{
  "ticker": "ONC",
  "company_name": "ONC",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05054348",
      "title": "First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Solid Tumor, Adult",
      "start_date": "2021-09-30",
      "completion_date": "2024-05-31",
      "enrollment": 0,
      "sponsor": "Immune-Onc Therapeutics"
    },
    {
      "nct_id": "NCT04372433",
      "title": "IO-202 as Monotherapy and IO-202 Plus Azacitidine \u00b1 Venetoclax in Patients in AML and CMML",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "AML With Monocytic Differentiation, CMML",
      "start_date": "2020-09-14",
      "completion_date": "2025-01-31",
      "enrollment": 0,
      "sponsor": "Immune-Onc Therapeutics"
    },
    {
      "nct_id": "NCT04524871",
      "title": "A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Advanced Liver Cancers",
      "start_date": "2020-11-01",
      "completion_date": "2026-12-31",
      "enrollment": 0,
      "sponsor": "Hoffmann-La Roche"
    },
    {
      "nct_id": "NCT05309187",
      "title": "Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Solid Tumor, Adult",
      "start_date": "2022-04-11",
      "completion_date": "2024-05-31",
      "enrollment": 0,
      "sponsor": "Immune-Onc Therapeutics"
    },
    {
      "nct_id": "NCT05508100",
      "title": "Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Advanced Solid Tumor",
      "start_date": "2022-09-09",
      "completion_date": "2024-04-30",
      "enrollment": 0,
      "sponsor": "Immune-Onc Therapeutics"
    }
  ],
  "summary": {
    "total_trials": 5,
    "by_phase": {
      "PHASE1": 4,
      "PHASE1, PHASE2": 1
    },
    "by_status": {
      "COMPLETED": 4,
      "RECRUITING": 1
    },
    "active_trials": 1,
    "completed_trials": 4,
    "conditions": [
      "AML With Monocytic Differentiation, CMML",
      "Advanced Liver Cancers",
      "Advanced Solid Tumor",
      "Solid Tumor, Adult"
    ],
    "lead_stage": "phase_1"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:48:09.501697",
    "search_query": "ONC",
    "url": "https://clinicaltrials.gov/search?term=ONC"
  }
}